Skip to main navigation Skip to search Skip to main content

CREST-2 findings are unchanged using an aggregated control group for the CAS and CEA trial

  • Piotr Musialek (Lead / Corresponding author)
  • , Krzysztof Malinowski
  • , Lukasz Tekieli
  • , Horst Sievert
  • , Anna Podlasek
  • , Adam Mazurek
  • , Renata Hatalska-Żerebiec
  • , Joachim Schofer
  • , Panagiotis Papanagiotou
  • , Iris Q. Grunwald

Research output: Contribution to journal › Article › peer-review

13 Downloads (Pure)

Abstract

Introduction
CREST-2 comprised two parallel observer-blinded randomised controlled trials evaluating carotid revascularisation (carotid artery stenting – CAS, or carotid endarterectomy – CEA) plus intensive medical management (IMM; supervised pharmacologic therapy and risk factor control and coached lifestyle modification) versus IMM alone in patients with asymptomatic ≥ 70% carotid stenosis. Each trial carried an independent IMM control arm. The primary endpoint (peri-procedural stroke/death or ipsilateral ischaemic stroke thereafter by 4 years) occurred, in the CAS trial, in 2.8% vs. 6.0% (IMM + CAS vs. IMM; p = 0.02). The effect of CEA did not reach significance; 3.7% vs. 5.3% (IMM + CEA vs. IMM; p = 0.24).

Aim
To test the hypothesis that the divergent control-arm event rates – rather than true differential efficacy of the interventional treatments – could underlie the CAS efficacy and CEA failure in CREST-2, we used a single combined control group as a balanced reference for both interventional treatment arms.

Material and methods
An Aggregated Control Group of IMM-only (n = 1,252) was formed by merging the CREST-2 IMM control arms patient data and outcomes. Kaplan-Meier analysis was performed for the CAS and CEA treatment vs. the Aggregated Control Group, consistent with the trial statistical methodology (intent-to-treat).

Results
In the Aggregated Control Group, the primary endpoint occurred in 5.65% of patients (95% CI: 4.47–7.12). Absolute risk reduction with CAS + IMM (n = 616) was 2.85% (relative risk reduction 50.4%; number-needed-to-treat 35, p = 0.0089). Absolute risk reduction with CEA + IMM (n = 617) was 1.95% (p = 0.0871, a maintained lack of statistical significance).

Conclusions
Aggregated Control Group analysis of CREST-2, minimising control arms biases, confirmed CAS efficacy (50.4% relative risk reduction) and maintained failure of CEA in primary prevention of ipsilateral stroke in patients with asymptomatic carotid stenosis under intensive medical management. This refutes control-arm disparity as an explanation for the divergent outcomes with CAS vs. CEA.
Original languageEnglish
Pages (from-to)178-189
Number of pages12
JournalPostepy w Kardiologii Interwencyjnej
Volume22
Issue number2
DOIs
Publication statusPublished - 30 Jun 2026

Keywords

  • asymptomatic carotid artery stenosis
  • carotid artery stenting
  • carotid atherosclerosis
  • carotid endarterectomy
  • carotid-related stroke
  • CREST-2
  • interventional therapy
  • medical management
  • stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'CREST-2 findings are unchanged using an aggregated control group for the CAS and CEA trial'. Together they form a unique fingerprint.

Cite this